Is AARD or ABCL more undervalued in 2026?

CirclFi compares Aardvark Therapeutics, Inc. (AARD) and AbCellera Biologics Inc. (ABCL) using 13 institutional-grade valuation models. AARD has a Quality of Company score of 5.6/10 while ABCL scores 7.3/10.

Which is a better buy — AARD or ABCL?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do AARD and ABCL valuations compare?

AARD at $4.20 and ABCL at $5.73 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

AARD vs ABCL Valuation Comparison 2026 — Intrinsic Value Analysis

AARD

Biotechnology

Aardvark Therapeutics, Inc.

Quality

5.6

out of 10

Value Trap

—

Price

$4.20

Last close

Models

9/13

Active

ABCL

Biotechnology

AbCellera Biologics Inc.

Quality

7.3

out of 10

Value Trap

SAFE

Price

$5.73

Last close

Models

10/13

Active

Model-by-Model Comparison

Model	Type	AARD Fair Value	AARD Upside	ABCL Fair Value	ABCL Upside
Bayesian DCF	Intrinsic	$2.43	-55.5%	$3.68	-35.8%
Earnings Power Value	Intrinsic	—	—	$1.35	-69.6%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$1.44	-65.8%	$1.59	-69.1%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for AARD vs ABCL — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

AARD vs ABCL — Which Stock Is More Undervalued?

ABCL scores higher with a 7.3/10 quality rating vs AARD's 5.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Aardvark Therapeutics, Inc. (AARD) and AbCellera Biologics Inc. (ABCL) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

AARD currently trades at $4.20 with a QOC of 5.6/10, while ABCL trades at $5.73 with a QOC of 7.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).